ArticleBritish journal of haematology2019
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review.Stem cell research & therapy · 2022Pooled it
- Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up.Frontiers in immunology · 2024Trial
- Critical care in hematopoietic stem cell transplantation: Common complications and management.World journal of critical care medicine · 2026Review
- Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation.Biomolecules · 2026Review
- Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.Blood · 2025Review
- The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.Bone marrow transplantation · 2025Article
- Mesenchymal stromal cells for steroid-refractory biopsy-proven grade III-IV acute Graft-versus-Host Disease with predominant gastrointestinal involvement.Frontiers in immunology · 2025Observational
- Cryopreserved apoptotic mesenchymal stromal cells retain functional efficacy in suppressing an allergic inflammation in a murine model.Stem cells translational medicine · 2024Article
- Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?American journal of respiratory and critical care medicine · 2024Article
- Efficacy of off-the-shelf bone marrow mesenchymal stem cells for pediatric steroid-refractory acute graft-versus-host disease.Blood cell therapy · 2024Article
- Current perspectives on mesenchymal stromal cell therapy for graft versus host disease.Cellular & molecular immunology · 2023Review
- Harnessing and honing mesenchymal stem/stromal cells for the amelioration of graft-versus-host disease.World journal of stem cells · 2023Review
- Article
- Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell.Stem cells translational medicine · 2022Article
- Successful treatment of steroid-dependent gastrointestinal acute graft-versus-host disease with mesenchymal stromal cells administered more than 100 days after allo-HCT.Blood cell therapy · 2022Article
- Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence.Bone marrow transplantation · 2021Article
- Neglected No More: Emerging Cellular Therapies in Traumatic Injury.Stem cell reviews and reports · 2021Review
- Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.Stem cells translational medicine · 2021Article
- Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?Blood reviews · 2021Review
- Treatment of Steroid-Refractory Acute Graft-Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid-resistant graft-versus-host-disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. We show that clinical responses assessed as early as 1 week after MSC infusion predict patients' overall survival. In our cohort, cell dose, patients' age and type of organ involvement are crucial factors associated with clinical responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.